InDevR appoints Dawn Bitz chief commercial officer

Wednesday June 29, 2016 0 comments Tags: Boulder, InDevR, Dawn Bitz, Kathy Rowlen

BOULDER -- InDevR,  a Boulder-based progressive analytical technology, life science instrumentation and medical device company, announced the appointment of Dawn Bitz as VP, Chief Commercial Officer, effective immediately.InDevR_logoUSE

Prior to joining InDevR, Bitz was a successful entrepreneur and executive holding $500M+ global P&L responsibilities, InDevR said.

“Dawn is a tremendous leader who will build a world-class commercial team at InDevR,” said Dr. Kathy Rowlen, company CEO. “Her experience in growing world-class businesses, planning and executing commercial strategies and overseeing multiple launches will play a critical role in InDevR’s next phase of growth.”

During her 20-plus-year career, Bitz has been a successful corporate executive, entrepreneur and consultant. She has held prominent positions with multi-billion dollar medical device and pharmaceutical companies, consulted for small and mid-cap companies, led mergers and integrations of $250M acquisitions, and has held $500M+ P&L responsibilities globally.

Early in her career she worked clinically on the ambulance and in the hospital and managing both pharmaceutical and medical device research studies. She translated that foundation into a successful business management and commercial career.

Bitz has led global marketing, sales, product development, business development and commercial operations for companies like Covidien, Boston Scientific and UCB Pharma. She also founded and sold a consumer product goods and technology company.

Bitz will lead InDevR’s commercial efforts, including product sales, marketing, business development and licensing, communications, public relations and investor relations.

Bitz holds undergraduate degrees in biology and chemistry from Texas Christian University and is a registered nurse and paramedic.

“I am excited to join InDevR at a time when we have the opportunity to shape commercial strategies for new and innovative ways to streamline and expedite the commercial vaccine production process,” Bitz said.

“I look forward to building and leading a top-tier organization that will impact our ability to fight influenza and other public health issues.”